Allergan says aesthetics unit revenue may double by 2025
NEW YORK (Reuters) – Allergan Plc said it expects revenue at its medical aesthetics unit to grow to $7 to $8 billion by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.
The Allergan logo is seen in this photo illustration November 23, 2015. REUTERS/Thomas White/Illustration/File Photo
Revenue from the business in 2017 was $3.8 billion, Allergan said. It said the forecast implies an 8 to 10 percent compound annual growth rate.
Reporting by Michael Erman; Editing by Chizu Nomiyama